1. Scrip
  2. >>R&D

Muted APPLAUSE For Novartis In IgAN

 
• By Elizabeth Cairns

A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.

Kidneys

That Novartis AG’s IgA nephropathy (IgAN) candidate iptacopan hit on proteinuria in its Phase III trial is good news, as far as it goes, but that is not very far. Without the extent of the product’s success over placebo having been disclosed, it is hard to gauge the drug’s effectiveness versus its peers.

Key Takeaways
  • Novartis is seeking accelerated approval for iptacopan in IgAN after an interim Phase III hit

The hit ought to be good enough to secure accelerated approval for iptacopan in the kidney disease. But Novartis’s chances...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.

Pharma Growth And Biotech Squeeze Will Shape Sector To 2030, Evaluate Forecasts

 
• By Andrew McConaghie

Evaluate’s five-year forecast sees steady growth for big pharma despite recent political turmoil but tougher times ahead for the ‘have nots’ of biotech.